3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Sarcoma
2
Melanoma
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
18
Nivolumab
7
Cyclophosphamide
6
fludarabine
5
Docetaxel
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Ipilimumab
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
poly ICLC
2
fludarabine phosphate
2
durvalumab
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Filgrastim
2
Biopsy
2
zimberelimab
1
veliparib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
trastuzumab deruxtecan
×
Dermatologic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled